Indiana to receive over $6M in EpiPen settlement

Indiana will receive $6.25 million as part of a settlement with global pharmaceutical companies over allegations that they conspired to increase the price of a prescription device called EpiPen by more than 600% on Hoosier consumers.

The product is used to inject adrenaline into patients to combat severe allergic reactions.

“Some pharmaceutical companies have prioritized profits over patients,” Attorney General Todd Rokita said. “But by demonstrating there are severe penalties for unlawful tactics to overcharge Hoosiers, we can deter this kind of conduct in the future.”

In January of 2025, Attorney General Rokita filed an antitrust lawsuit alleging that Viatris Inc., Pfizer Inc. and other companies conspired to increase prices in order to maximize the money made from EpiPen prescriptions and prevent other similar products from coming to market and being available to consumers. Viatris was formed via a 2020 merger of Mylan and Upjohn, a Pfizer subsidiary.

The complaint alleged the companies, and their subsidiaries violated the Indiana Deceptive Consumer Sales Act, the Indiana Antitrust Act and the Medicaid False Claims Act by continually increasing the price of EpiPens and providing payments to pharmacy benefit managers (PBMs) to exclude competition.

The lawsuit also asserted the companies paid doctors to endorse their decision to launch a 2-pack of the EpiPen and claim it is medically necessary — allowing the companies to cease selling individual EpiPens.

As part of the settlement, the companies deny any wrongdoing.